News Almirall, S.A.

Stocks

ALM

ES0157097017

Pharmaceuticals

Market Closed - BME Other stock markets 11:35:28 2026-07-21 EDT			After hours 13:56:04
10.90 ^EUR	-0.37%		10.91	+0.09%

06-30	Armirall Sells Actithiol Franchise for EUR15 Million	MT
06-25	Moody's Upgrades Almirall's Rating on Revenue Growth Outlook Through 2030	MT

All News

Mentions Relevance

07-20	Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older	BU
06-30	Armirall Sells Actithiol Franchise for EUR15 Million	MT
06-25	Moody's Upgrades Almirall's Rating on Revenue Growth Outlook Through 2030	MT
05-12	Almirall amends weighted average price of share for scrip dividend	RE
05-11	Almirall, S.A. Reiterates Earnings Guidance for the Full Year 2026	CI
05-11	Almirall, S.A. Approves Dividend	CI
05-11	Almirall, S.A., Q1 2026 Earnings Call, May 11, 2026
05-11	Almirall approves fully paid-up capital increase for flexible dividend	RE
05-11	Almirall Continues Its Positive Trajectory in Q1 2026 in Line With Expectations – Led by 19.3% YoY Growth of Its European Dermatology Business	BU
05-11	Almirall Q1 normalized net profit 16.1 mln euros	RE
05-10	Almirall, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-13	Almirall S.A. And Barcelona Supercomputing Center Expand Collaboration To Accelerate Innovation In Medical Dermatology	CI
04-13	Almirall expands collaboration with Barcelona Supercomputing Center to boost dermatology research	RE
04-13	Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology	BU
04-09	Almirall sets its sights on gains with Jefferies support
04-07	Almirall proposes payment of dividend out of unrestricted reserves of 40.8 mln euros	RE
03-30	Almirall enters collaboration with Huaota for the development of a novel monoclonal antibody in medical dermatology	AQ
03-27	Almirall S.A. Presents Long-Term Disease Control Results For Lebrikizumab In Moderate-To-Severe Atopic Dermatitis	CI
03-27	Almirall says lebrikizumab shows control in atopic dermatitis for up to four years	RE
03-27	Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis	BU
03-27	Almirall enters collaboration with Huaota for development of monoclonal antibody in medical dermatology	RE
03-27	Zhejiang Huahai Pharmaceutical's unit signs global research and licensing deal with Almirall, S.A.	RE
03-26	AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne	BU
03-26	Almirall S.A. Presents New Clinical and Real-World Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne	CI
03-23	Almirall's 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology	BU